利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.034 秒)

    Transscleral delivery
    3.
    发明授权
    Transscleral delivery 有权
    跨收运

    公开(公告)号：US07585517B2

    公开(公告)日：2009-09-08

    申请号：US10945682

    申请日：2004-09-20

    申请人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J M Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J M Dor ,  Sreenivasu Mudumba

    IPC分类号： A61F2/00 ,  C12P21/04 ,  A61K38/00 ,  A61K31/44 ,  A61K31/445

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    TRANSSCLERAL DELIVERY
    5.
    发明申请
    TRANSSCLERAL DELIVERY 审中-公开
    TRANSSCLERAL交货

    公开(公告)号：US20120034279A1

    公开(公告)日：2012-02-09

    申请号：US13279179

    申请日：2011-10-21

    申请人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. COOPER ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe JM Dor ,  Sreenivasu Mudumba

    IPC分类号： A61K9/14 ,  A61P27/02 ,  A61K31/439

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    TRANSSCLERAL DELIVERY
    6.
    发明申请
    TRANSSCLERAL DELIVERY 审中-公开
    TRANSSCLERAL交货

    公开(公告)号：US20090324690A1

    公开(公告)日：2009-12-31

    申请号：US12541866

    申请日：2009-08-14

    申请人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J. M. Dor ,  Sreenivasu Mudumba

    发明人： Eugene R. Cooper ,  David M. Kleinman ,  Thierry Nivaggioli ,  Philippe J. M. Dor ,  Sreenivasu Mudumba

    IPC分类号： A61K9/00 ,  A61K31/436 ,  A61P27/02

    CPC分类号： A61K9/0048 ,  A61K9/0019 ,  A61K31/436

    摘要： Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.

    摘要翻译： 通过将这些组织交叉施用治疗剂，可以有效地治疗与眼后段组织相关的疾病。 用于递送治疗剂使得它们穿过巩膜并到达这些组织的组合物，装置和方法包括在巩膜附近或在巩膜附近注射溶液或悬浮液，并植入包含与巩膜内或巩膜内的治疗剂的固体结构。 这些方法可用于施用雷帕霉素或相关化合物以治疗与年龄相关的黄斑变性相关的脉络膜新生血管形成。

    FORMULATIONS FOR TREATING OCULAR DISEASES AND CONDITIONS
    7.
    发明申请
    FORMULATIONS FOR TREATING OCULAR DISEASES AND CONDITIONS 有权
    治疗卵巢疾病和病症的制剂

    公开(公告)号：US20090074786A1

    公开(公告)日：2009-03-19

    申请号：US12193686

    申请日：2008-08-18

    申请人： Philippe J.M. Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David A. Weber ,  Sidiq Farooq ,  Sudeep K. Takhar

    发明人： Philippe J.M. Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David A. Weber ,  Sidiq Farooq ,  Sudeep K. Takhar

    IPC分类号： A61K31/436 ,  A61P27/02 ,  A61K39/395

    CPC分类号： A61K31/436

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。 液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。 可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 液体制剂可以包含雷帕霉素或其它治疗剂。

    LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
    8.
    发明申请
    LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS 有权
    用于治疗疾病或病症的液体制剂

    公开(公告)号：US20100227879A1

    公开(公告)日：2010-09-09

    申请号：US12778872

    申请日：2010-05-12

    申请人： Sreenivasu Mudumba ,  Philippe J.M. Dor ,  Thierry Nivaggioli ,  David A. Weber ,  Sidiq Farooq

    发明人： Sreenivasu Mudumba ,  Philippe J.M. Dor ,  Thierry Nivaggioli ,  David A. Weber ,  Sidiq Farooq

    IPC分类号： A61K31/436 ,  A61P27/02

    CPC分类号： A61K9/0046 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/045 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age-related macular degeneration in a subject. The liquid formulations may comprise rapamycin or other therapeutic agents.

    摘要翻译： 包括但不限于眼睛中的组织的疾病和病症可被有效治疗，预防，抑制，发作延迟或由给予这些组织的治疗剂引起的回归。 本文描述的是液体制剂，其将多种治疗剂（包括但不限于雷帕霉素）递送给受试者较长时间; 当被置于受试者的水性介质中时形成非分散物质的液体制剂; 在水性介质中形成凝胶或凝胶状物质的非分散质量形成液体制剂; 液体制剂，包含治疗剂和多种聚合物; 以及使用液体制剂将治疗剂递送给受试者较长时间的方法。 液体制剂可以放置在受试者的水性介质中，包括但不限于通过眼内或眼周内施用，或靠近受试者待治疗的疾病或病症的位置放置。 可以使用方法来施用雷帕霉素以治疗或预防受试者的血管生成，脉络膜新生血管形成或年龄相关性黄斑变性或湿性年龄相关性黄斑变性。 液体制剂可以包含雷帕霉素或其它治疗剂。

    Formulations for ocular treatment
    10.
    发明申请
    Formulations for ocular treatment 审中-公开
    眼部治疗剂型

    公开(公告)号：US20060182771A1

    公开(公告)日：2006-08-17

    申请号：US11351844

    申请日：2006-02-09

    申请人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    发明人： Philippe Dor ,  Sreenivasu Mudumba ,  Thierry Nivaggioli ,  David Weber

    IPC分类号： A61K31/4745 ,  A61K9/00

    CPC分类号： A61K9/0046 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/045 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K47/44

    摘要： Diseases and conditions associated with tissues of the body, including tissues in the eye, can be effectively treated by administering therapeutic agents to those tissues. Described herein are self-emulsifying formulations and methods for delivering therapeutic agents to such tissues. A self-emulsifying formulation may be delivered to an aqueous medium of a subject, including but not limited to the vitreous. A method may, for instance, be used to administer rapamycin or related compounds to treat or prevent choroidal neovascularization associated with age-related macular degeneration, or to treat dry AMD. A self-emulsifying formulation may also be administered systemically, such as orally, to treat transplant rejection in a subject. A self-emulsifying formulation may comprise rapamycin, related compounds, or other therapeutic agents.

    摘要翻译： 可以通过向这些组织施用治疗剂来有效地治疗与身体组织（包括眼睛中的组织）相关的疾病和病症。 本文描述了将治疗剂递送到这种组织的自乳化制剂和方法。 自乳化制剂可以递送到受试者的水性介质，包括但不限于玻璃体。 例如，可以使用方法来施用雷帕霉素或相关化合物以治疗或预防与年龄相关性黄斑变性相关的脉络膜新血管形成，或治疗干性AMD。 自乳化制剂也可以全身施用，例如口服给药以治疗受试者的移植排斥。 自乳化制剂可以包含雷帕霉素，相关化合物或其它治疗剂。